Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. (Q51062105)

28 March 2018

title

Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. (English)

1 reference

28 March 2018

main subject

phase I clinical trial

0 references

0 references

1 reference

M Danchin

1

1 reference

28 March 2018

C D Kirkwood

2

1 reference

28 March 2018

K J Lee

3

1 reference

28 March 2018

R F Bishop

4

1 reference

28 March 2018

E Watts

5

1 reference

28 March 2018

F A Justice

6

1 reference

28 March 2018

V Clifford

7

1 reference

28 March 2018

D Cowley

8

1 reference

28 March 2018

J P Buttery

9

1 reference

28 March 2018

J E Bines

10

1 reference

28 March 2018

language of work or name

English

0 references

publication date

16 April 2013

1 reference

28 March 2018

published in

Vaccine

1 reference

28 March 2018

volume

31

1 reference

28 March 2018

issue

23

1 reference

28 March 2018

page(s)

2610-2616

1 reference

28 March 2018

Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Protective effect of natural rotavirus infection in an Indian birth cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Intussusception among infants given an oral rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Early phase II trial of human rotavirus vaccine candidate RV3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Serum, fecal, and breast milk rotavirus antibodies as indices of infection in mother-infant pairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Bowel habits of healthy Australian children aged 0-2 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Rotavirus vaccines: viral shedding and risk of transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.008

10.1016/J.VACCINE.2013.04.008

7 January 2021

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

23597719

1 reference

28 March 2018